Tandem Diabetes Care, Inc.: FDA filings under this applicant name

FDA lists 24 510(k) clearances under 2 spellings of the applicant name “Tandem Diabetes Care, Inc.” (first 2011, latest 2026), plus 2 PMA and 2 De Novo decisions, across 8 product codes in 2 review panels. Median 510(k) review time under this name: 88 days. Since 2017 the median was 74 days, against 189 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.

510(k) clearances per year

YearClearancesMedian review days
20120—
20131203
20142122
2015165
20163142
20170—
20180—
20190—
2020373
20210—
20221469
2023487
2024273
2025568
2026173

Review time against the same product codes

Since 2017, 510(k)s cleared under the name Tandem Diabetes Care, Inc. took a median 74 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 189 days.

Top product codes

Product codeDeviceSubmissions510(k) clearances
QFGAlternate Controller Enabled Insulin Infusion Pump109
LZGPump, Infusion, Insulin77
QJIInteroperable Automated Glycemic Controller65
FPASet, Administration, Intravascular11
OUGMedical Device Data System11
OYCPump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor10
OZOAutomated Insulin Dosing , Threshold Suspend10
QJSInteroperable Automated Glycemic Controller, Insulin Suspend11

Review panels

Most recent Tandem Diabetes Care, Inc. 510(k) clearances

510(k)DeviceProduct codeDecision dateReview days
K260429Control-IQ+ technologyQJI2026-04-2473
K253074Tandem Mobi insulin pump with interoperable technologyQFG2025-11-0644
K250792t:slim X2 insulin pump with interoperable technologyQFG2025-09-24194
K251854SteadiSet infusion setFPA2025-08-0650
K250798Control-IQ+ technologyQJI2025-05-2168
K243823Control-IQ+ technologyQJI2025-02-2474
K241078Tandem Mobi Insulin Pump with interoperable technologyQFG2024-07-2698
K240309Tandem Mobi insulin pump with interoperable technologyQFG2024-03-2148
K232382Control-IQ TechnologyQJI2023-11-0387
K232380t:slim X2 Insulin Pump with Interoperable TechnologyQFG2023-11-0387

14 earlier clearances. See the full list in Caduvo.

PMA and De Novo decisions

NumberPathwayDeviceDecision date
DEN190034De NovoInteroperable Automated Glycemic Controller2019-12-13
DEN180058De NovoAlternate Controller Enabled Insulin Infusion Pump2019-02-14
P180008PMAt:slim X2 Insulin Pump with Basal-IQ Technology2018-06-21
P140015PMAT:SLIM G4 INSULIN PUMP WITH DEXCOM G4 PLATINUM CGM2015-09-08

Recalls

15 product recalls in 13 recall events; 12 initiated in the last five years. Most recent: 2026-09-23.

Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.

Device clinical trials

An industry sponsor named Tandem Diabetes Care, Inc. is the lead sponsor of 17 device studies on ClinicalTrials.gov (1 active or recruiting). Most recent:

SEC filings

TANDEM DIABETES CARE INC (TNDM): EDGAR filings, CIK 1438133. An SEC registrant with the same name, matched by name only.

Related HCPCS codes

HCPCS Level II codes whose descriptors match the device names of the product codes filed under Tandem Diabetes Care, Inc. (a text match, not an official crosswalk):

FDA spellings included

FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:

Other FDA applicant names starting with the same word

FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.

Frequently asked questions

How many FDA 510(k) clearances are listed under Tandem Diabetes Care, Inc.?

FDA lists 24 510(k) clearances under 2 spellings of the applicant name “Tandem Diabetes Care, Inc.” (first 2011, latest 2026), plus 2 PMA and 2 De Novo decisions, across 8 product codes in 2 review panels. Filings under other applicant names, such as subsidiaries, are not included.

How long has FDA taken to clear 510(k)s filed by Tandem Diabetes Care, Inc.?

The median time from FDA receipt to decision across 510(k)s cleared under the name Tandem Diabetes Care, Inc. is 88 days. Since 2017: 74 days, versus 189 days for all cleared 510(k)s in the same product codes.

Which FDA product codes appear under Tandem Diabetes Care, Inc.?

The most frequent FDA product codes under this applicant name are QFG (Alternate Controller Enabled Insulin Infusion Pump, 10); LZG (Pump, Infusion, Insulin, 7); QJI (Interoperable Automated Glycemic Controller, 6).

Next steps

Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.

All FDA device companies · FDA product code lookup